RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Deciphera Pharmaceuticals Stock

Deciphera Pharmaceuticals ROA 2024

Deciphera Pharmaceuticals ROA

-0.41

Ticker

DCPH

ISIN

US24344T1016

WKN

A2H48H

In 2024, Deciphera Pharmaceuticals's return on assets (ROA) was -0.41, a 4.46% increase from the -0.39 ROA in the previous year.

Deciphera Pharmaceuticals Aktienanalyse

What does Deciphera Pharmaceuticals do?

Deciphera Pharmaceuticals Inc is a US biopharmaceutical company specializing in the research, development, and marketing of innovative therapeutic solutions for cancer patients. The company was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera follows a diversified business model based on multiple pillars. On one hand, the company conducts its own research and development activities to develop new therapy approaches for cancer patients. Deciphera focuses on the research of kinase inhibitors, which offer promising approaches in cancer therapy. On the other hand, the company pursues a licensing strategy by acquiring and further developing already developed active ingredients for cancer therapies in order to make them available to patients. For this purpose, the company collaborates with various partner companies and leading academics and experts in the field of cancer therapy. Deciphera is also engaged in international collaboration through partnerships with local partners in Asia for the research of new cancer therapy approaches. The company invests significant efforts in research and development to constantly adapt its products to the latest scientific advances. Deciphera aims to develop effective and safe therapies for cancer patients that improve their quality of life and increase their chances of survival. The company relies on the research of kinase inhibitors that specifically target certain signaling pathways in cancer cells and thereby inhibit the growth of tumor cells. The company already has a number of products in clinical trials and approval processes that show promising results and are expected to be on the market soon. One promising drug is Ripretinib, dedicated to the cancer type GIST. The goal is to offer a range of cancer medications that have significant treatment success and offer customers high chances of success. Overall, Deciphera Pharmaceuticals is a dynamic and research-oriented company that utilizes the most innovative technologies to give hope to cancer patients and improve the treatment of cancer diseases. With its broad portfolio of active ingredients and therapy approaches, its international presence, and its dedicated research and development, Deciphera Pharmaceuticals Inc. is at the forefront when it comes to innovative cancer treatment therapies. Deciphera Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Deciphera Pharmaceuticals's Return on Assets (ROA)

Deciphera Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Deciphera Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Deciphera Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Deciphera Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Deciphera Pharmaceuticals stock

What is the Return on Assets (ROA) of Deciphera Pharmaceuticals this year?

The Return on Assets (ROA) of Deciphera Pharmaceuticals is -0.41 undefined this year.

What was the ROA of Deciphera Pharmaceuticals compared to the previous year?

The ROA of Deciphera Pharmaceuticals has increased by 4.46% compared to the previous year.

What consequences do high ROA have for investors of Deciphera Pharmaceuticals?

A high ROA is advantageous for investors of Deciphera Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Deciphera Pharmaceuticals?

A low ROA can be unfavorable for investors of Deciphera Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Deciphera Pharmaceuticals affect the company?

An increase in ROA of Deciphera Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Deciphera Pharmaceuticals impact the company?

A reduction in the ROA of Deciphera Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Deciphera Pharmaceuticals?

Some factors that can influence the ROA of Deciphera Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Deciphera Pharmaceuticals important for investors?

The ROA of Deciphera Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Deciphera Pharmaceuticals take to improve ROA?

To improve ROA, Deciphera Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Deciphera Pharmaceuticals pay?

Over the past 12 months, Deciphera Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Deciphera Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Deciphera Pharmaceuticals?

The current dividend yield of Deciphera Pharmaceuticals is .

When does Deciphera Pharmaceuticals pay dividends?

Deciphera Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Deciphera Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Deciphera Pharmaceuticals located?

Deciphera Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Deciphera Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Deciphera Pharmaceuticals from 11/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Deciphera Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Deciphera Pharmaceuticals in the year 2023?

In the year 2023, Deciphera Pharmaceuticals distributed 0 USD as dividends.

In which currency does Deciphera Pharmaceuticals pay out the dividend?

The dividends of Deciphera Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Deciphera Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Deciphera Pharmaceuticals

Our stock analysis for Deciphera Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Deciphera Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.